Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 9312345...102030...Last »

Allergan and Sosei Halt Alzheimer’s Study

Allergan and the company’s development partner Sosei Group voluntarily suspended clinical trials of HTL0018318 in Alzheimer’s and other types of dementia because of safety problems.

Read More »

AstraZeneca Plans to Seek Regulatory Approval for COPD Drug PT010 Following Phase III Trial

Following a setback in a chronic obstructive pulmonary disease (COPD) clinical trial in August, AstraZeneca unveiled data from a separate trial that showed the triple combination therapy PT010 outperformed dual-therapy rivals eight of nine times.

Read More »

R&D Cooperation Between China and Western Pharma Companies Up 70 Percent

China has become one of the most important markets for pharma companies, given the vast patient population and the rising cancer rates, and western pharmaceutical companies are making greater inroads there.

Read More »

Half of Europe’s clinical trials fail to report results

Almost half of all European-registered clinical trials have breached EU rules by failing to report results, according to a published analysis.

Read More »

Doctors offer advice for insomnia

People who have trouble falling asleep and staying asleep may want to seek advice from a doctor and avoid long-term use of sleeping pills, medical experts advise.

Read More »

Cancer deaths to rise to 9.6 million in 2018

Cancer will claim the lives of 9.6 million people in 2018, accounting for one in eight of all deaths among men and one in 11 among women, the WHO’s cancer research agency said.

Read More »

Vital Therapies shares dive as liver system fails trial

Vital Therapies Inc. will explore strategic options after the U.S. biotech firm’s liver disease treatment failed to meet the main goal of a late-stage study, driving its shares down more than 70 percent.

Read More »

Galapagos soars on $4-6 billion hopes for new drug

Strong results for an experimental drug that promises to disrupt the rheumatoid arthritis market lifted shares in Galapagos to an all-time high as analysts forecast multibillion-dollar sales.

Read More »

Bristol-Myers plaque psoriasis drug shows promise in mid-stage trial

Bristol-Myers Squibb’s experimental drug BMS-986165 helped reduce the severity of the most common form of psoriasis in a mid-stage trial.

Read More »

Foamix acne drug meets main goals in late-stage trial, shares surge

Foamix Pharmaceuticals Ltd.’s lead drug for treating moderate-to-severe acne met the main goals of the company’s third late-stage study, sending its shares up 57 percent in extended trading.

Read More »

Amgen’s Aimovig Starts Strong, Multiple Myeloma Drug Wows at Conference

Amgen unveiled data at a multiple myeloma conference for AMG-420, which targets B-cell maturation antigen (BCMA).

Read More »

EpicGenetics and Massachusetts General Hospital to Launch Fibromyalgia Clinical Trial

EpicGenetics and Massachusetts General Hospital are launching a Phase II clinical trial to test a tuberculosis vaccine, CBG, as a potential treatment for fibromyalgia.

Read More »

Merck KGaA, Pfizer’s immuno-drug shown to alleviate kidney cancer

Merck KGaA said the immunotherapy Bavencio, jointly developed with Pfizer Inc., delayed the progression of kidney cancer when used in combination with Pfizer’s Inlyta drug in a late-stage study.

Read More »

One in three U.S. teens text while driving, survey shows

One in three teen drivers in the U.S. text while driving, new survey data suggests, and the number may be higher in states where teens start driving at younger ages.

Read More »

Lilly Announces Initiation of IXORA-R Head-to-Head Trial Comparing Taltz and Tremfya in Patients with Moderate-to-Severe Plaque Psoriasis

Eli Lilly and Company announced today the initiation of the IXORA-R head-to-head clinical trial, designed to evaluate superiority between Taltz (ixekizumab) and Tremfya (guselkumab) in adult patients with moderate-to-severe plaque psoriasis.

Read More »

Consort, Opiant to develop nasal spray for opioid overdose treatment

Britain’s Consort Medical Plc agreed to develop a nasal spray for treating opioid overdoses with specialty pharmaceutical company Opiant Pharmaceuticals Inc.

Read More »

Tezepelumab Granted Breakthrough Therapy By FDA

Amgen and AstraZeneca announced that the U.S. FDA granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma without an eosinophilic phenotype.

Read More »

Dementia risk doubles right after a stroke

People who have recently experienced a stroke may be more than twice as likely to develop dementia than individuals who have not had a stroke, a new study suggests.

Read More »

With Phase II Win for Ankylosing Spondylitis, Gilead and Galapagos’ Filgotinib Inches Toward Approval

Gilead Sciences Inc. and its partner Galapagos NV announced results from the Phase II TORTUGA clinical trial of filgotinib, a selective JAK1 inhibitor, in adults with moderately to severely active ankylosing spondylitis.

Read More »

Checkmate Pharmaceuticals Announces Strategic Collaboration with Merck KGaA, Pfizer

Checkmate Pharmaceuticals announced a clinical trial collaboration and supply agreement with the alliance between Merck KGaA and Pfizer Inc. to evaluate the TLR9 agonist CMP-001 in combination with the human anti-PD-L1 antibodyavelumab.

Read More »

Page 1 of 9312345...102030...Last »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!

Subscribe

Ad Right Bottom